Literature DB >> 21623493

Gluten contamination in the Canadian commercial oat supply.

T B Koerner1, C Cléroux, C Poirier, I Cantin, A Alimkulov, H Elamparo.   

Abstract

A growing body of evidence suggests that a majority of people with celiac disease and on a gluten-free diet can safely consume pure oats in moderate amounts; however, previous studies have indicated that the commercial oat supply in other countries, and in Canada to some extent, is contaminated with other grains. This study has confirmed that the commercial oat supply in Canada is heavily contaminated with gluten from other grains. Approximately 88% of the oat samples (n = 133) were contaminated above 20 mg kg(-1) and there were no differences between the oat types tested. Only one gluten-free variety of oats was analysed and it consistently provided negative results in all analyses. It is difficult to determine where the contamination originates, but there are possibilities for cross-contamination in the field, in the transport of the grain, in the storage of the grain, and in the milling and packaging facilities. It is clear from this study that only those products that have been certified 'pure' oats would be appropriate for a gluten-free diet.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21623493      PMCID: PMC3118497          DOI: 10.1080/19440049.2011.579626

Source DB:  PubMed          Journal:  Food Addit Contam Part A Chem Anal Control Expo Risk Assess        ISSN: 1944-0057


Introduction

Food allergies and intolerances are two sensitivities that, although they have distinct physiological pathways, require the strict avoidance of specific triggering substances. Wheat is one of these triggers and is among the eight most common food allergens identified by the Codex Alimentarius (Codex Alimentarius Commission 2010). Overall, food allergies affect approximately 5% of young children and 3–4% of adults (Sicherer and Sampson 2010). Prevalence data from adult and paediatric clinical populations suggest that wheat allergy can range from 2.5% in one American study to 25% of the allergenic population in one study from France (Hischenhuber et al. 2006). Adverse reactions to wheat can be severe, such as wheat-dependent exercise-induced anaphylaxis, but reactions can also include respiratory (e.g. bakers’ asthma), contact (e.g. atopic eczema/dermatitis), or gastrointestinal problems such as irritable bowel syndrome and ulcerative colitis (Battais et al. 2005). Celiac disease is an inherited autoimmune disease that results in an intolerance not only to wheat, but also to other cereals such as barley and rye. It is estimated to affect approximately 0.5–1.0% of people in developed countries (Catassi and Fasano 2008) and its prevalence is on the rise (Rubio-Tapia and Murray 2010). Fortunately, withdrawal of the gluten-containing foods from the diet can, in most cases, reverse this damage and a significant recovery of the intestinal mucosa is observed (Farrell and Kelly 2002). Given the ubiquitous presence of these cereals in the Western diet (e.g. pasta, breakfast cereals, most breads, thickeners and stabilizers used in soups, processed meats, etc.), the strict avoidance of wheat and other sources of gluten is a lifetime challenge (Rashtak and Murray 2009). Individuals on a gluten-free diet need to replace these cereals with products derived from naturally gluten-free cereal grains (e.g. rice, corn, buckwheat, sorghum, etc.), but the recommended amounts of fibre, iron and calcium can be more difficult to obtain on such a diet and good planning is required (Thompson et al. 2005). Oats are known to be a source of both soluble and insoluble dietary fibre, B-complex vitamins (thiamin, niacin and riboflavin), iron and proteins (Thompson 2003; Haboubi et al. 2006). However, the safety of oats as part of a gluten-free diet has been an object of debate because there is evidence to indicate some individuals with celiac disease are intolerant to oats in addition to wheat, barley and rye (Silano et al. 2007). The complexity of celiac disease along with a certain homology in the protein fraction of oats with other gluten-containing cereals is likely to be the reason why some individuals react to oats. However, there is a significant difference between the proteins found in oats and the immuno-stimulatory protein sequences found in wheat, rye and barley which may explain why most people with celiac disease are able to tolerate these cereal grains (Pulido et al. 2009). In fact, there is a growing body of evidence to suggest that pure oats (uncontaminated with other gluten-containing cereal grains) are safe to consume in moderate amounts for the majority of people suffering from celiac disease and would be very important source of proteins, carbohydrates and fibre (Rashid et al. 2007). Canada has established requirements for the production of uncontaminated oats including the growing, processing, testing and labelling stages of the product. It cannot be assumed that all varieties of oats sold in Canada are uncontaminated with other gluten sources because the infrastructure used for growing, transporting and milling of other grains may be used for oats and cross-contamination is likely to occur. There have been a few studies that have shown the likelihood and levels to which oat varieties are contaminated with other gluten-containing cereals, but most of these investigations were on oats sold in the United States and Europe and only two had limited information on varieties sold in Canada (Thompson 2004; Hernando et al. 2006, 2008; Gélinas et al. 2008). To obtain a better picture of gluten contamination within the oat varieties sold at Canadian retailers we collected a large sampling from across the country for a variety of different oat products.

Materials and methods

Food samples

Oat samples were collected from retail outlets in Newfoundland, Prince Edward Island, Quebec, Ontario and British Columbia at two different times in the year to ensure that at least two samples with distinct lot codes could be collected. Mixing four samples of each lot in a large bowl by hand produced a composite material, of which approximately 1 kg was finely ground to between 100 and 200 microns using a centrifugal mill (Retsch Mill ZM 200, Haan, Germany). The milled samples were then homogenized by mixing for 30 min with a 1000W industrial stand mixer (Cuisinart, Model #SM-70C) to produce a finely ground homogenized composite oat material. A 200 g subsampling of this material was then stored for analysis. The centrifugal mill and the stand mixer components were disassembled between samples for cleaning with copious amounts of hot water and allowed to air dry. Samples collected in British Columbia were processed in a slightly different manner (n = 35 of 133). Composite samples of approximately 500 g were milled using a commercial blender (Waring, Torrington, CT, USA) before homogenization with a bottle roller.

ELISA systems

Gluten analysis was performed in duplicate using the RIDASCREEN R-7001 gliadin ELISA (R-Biopharm Inc., Washington, MO, USA). This kit performs the quantitative analysis of prolamins from wheat (gliadins), barley (hordeins) and rye (secalins). The gliadin standards supplied with the kit are calibrated to the Prolamin Working Group reference material with a limit of detection of 3 mg of gluten per kg of sample and a quantification range for gluten from 5 to 80 mg kg−1 (Van Eckert et al. 2006). The kit instructions were followed for this analysis and the procedure is only briefly described here. The nature of the oat flour samples did not require any special extraction solutions so the ethanol extraction process described in the kit insert was used for the analysis. Each sample of oats (1.0 g) was weighed into a 15 ml centrifuge tube, a 60% aqueous ethanol solution (10 ml) was added and the tubes were put on a vortex for 30 s. Samples were mixed for an additional 10 min on a shaker (VWR 0S-500) followed by centrifugation at room temperature for 10 min at 2500 g (ThermoFisher Sorvall RT-1). A measured aliquot of the supernatant was removed; diluted 50 times and then 100 μl of this solution were used in the assay. Standards and samples were added in duplicate wells on the plate and allowed to incubate for 30 min at room temperature followed by three washing steps. Enzyme conjugate was added to each well and the plate was incubated for 30 min followed by an additional three washing steps. At this point substrate and chromogen were added to each well and allowed to react for 30 min followed by the addition of stop reagent. The absorbance was read at 450 nm and the data analysed to determine gluten concentration. The plate results are given in gliadin concentration and need to be adjusted for the dilution factor to obtain the gliadin concentration in solution, which is then converted to gluten content by multiplication by two. All samples that showed an absorbance value over the highest standard were further diluted until the results were within the calibration range. An ELISA from Tepnel Biosystems (BioKits line of ELISA kits are now being distributed by Neogen, Lansing, MI, USA; http://www.neogen.com) was used to screen a subset of the original samples for barley contamination. This particular kit uses an antibody that recognizes ω-gliadin, which has a low cross-reactivity to barley hordeins (5%) compared with wheat gliadin (100%). The limit of detection for this assay is 1 mg kg−1 of material and the quantification range is from 3 to 50 mg kg−1 of gluten in a sample.

Results and discussion

There is scientific evidence to support the introduction of moderate amounts of pure oats in the gluten-free diet of individuals suffering from celiac disease (Pulido et al. 2009). Pure oats are recommended because it is believed, and has been shown to some extent, that the commercial oat supply is contaminated with other grains. In order to determine the extent of this contamination we analysed a large selection of packaged oat products that are readily available in the Canadian retail market. Figure 1 shows the gluten levels determined for the oat composites tested in this study using the RIDASCREEN® R-7001 sandwich ELISA (R5-ELISA). Of the 133 samples analysed only nine (6.8%) were found to contain levels of gluten below the 20 mg kg−1 limit proposed by the Codex Alimentarius Commission for naturally gluten-free foods (Catassi and Fasano 2008). Three of these samples had undetectable amounts of gluten, while the remaining samples were between 5 and 20 mg kg−1. The remaining samples (n = 124, 93.2%) showed contamination levels above this limit and ranged from approximately 21 to 3800 mg kg−1. Previous studies that have measured the gluten content in oats had a limited number of samples from the Canadian market, but showed similar contamination levels to this study. For example, one study found eight of 12 samples of oats purchased in Canada (67%) were contaminated (Gélinas et al. 2008) while another found that seven of ten samples purchased in Canada (70%) were contaminated with gluten at levels higher than 20 mg kg−1 (Hernando et al. 2008).
Figure 1.

Survey results of the average gluten levels in a sampling of pre-packaged oats sold in Canadian retail stores using a commercial ELISA kit. The insert is an expanded region of the lower-level samples along with a line representing the 20 mg kg−1level recommended by CODEX for gluten-free status.

Another aspect of this study that is of interest is the variance within different lots of commercial oats sold in Canada. Is it possible to find a brand of oats that is consistently low in gluten? As mentioned above there were three samples of oats that showed undetectable levels of gluten using the R5-ELISA. Two of these samples were different lots from the one company and the last sample was part of a set of six different lots of rolled oats from a different company. The former two lots of oats from one company tested negative for gluten while the six lots from the other company ranged from zero to 133 mg kg−1 of oats. This was not an isolated example and all oat types showed variance within the different lots sold in Canada. The variability between different types of oats available on the Canadian market was also investigated by determining the average gluten level for the different types of oats (Table 1). Analysis of variance (ANOVA) for the different oat samples confirms there is no significant difference between the oat types (ρ = 0.06). Interestingly, analysis of the data obtained for regular and organic oats shows that there is a significant difference (ρ < 0.0001) between organic oats (mean = 240 mg kg−1, n = 31) and regular oats (mean = 616 mg kg−1, n = 102), but this crop is still significantly contaminated with gluten.
Table 1.

Gluten content as a function of type of oat product.

Type of oatRange (mg kg−1)Median (mg kg−1)Mean (mg kg−1)
Steel-cut oats55–1467660645 ± 512
Rolled/flaked/oatmeal0–248581316 ± 497
Quick/minute oats13–3784534655 ± 694
Oat bran37–3469280704 ± 862
Gluten content as a function of type of oat product. Survey results of the average gluten levels in a sampling of pre-packaged oats sold in Canadian retail stores using a commercial ELISA kit. The insert is an expanded region of the lower-level samples along with a line representing the 20 mg kg−1level recommended by CODEX for gluten-free status. In order to determine the type of grain that has contaminated the oat samples a selection of oat types purchased were analysed again using an ELISA method that is insensitive to barley hordeins. The R5-ELISA responds to a peptide sequence that is present in gliadin and then reports the amount of gluten by referencing to a gliadin material based on multiple wheat cultivars (Van Eckert et al. 2006). This assay also responds to barley and rye because the same peptide sequence is present in hordeins and secalins; however, the gluten assay that responds to the ω-gliadin fraction of wheat has a low cross-reactivity (5%) towards barley hordeins. A high response from the R5-ELISA and a low response from the ω-ELISA is an estimate of the type of gluten contamination (Gélinas et al. 2008). For example, the level of gluten for sample 63 (Figure 2) using the R5-ELISA was determined to be 216 mg kg−1 while the level for the same sample using the ω-gliadin ELISA was only 10 mg kg−1. The response from the ω-ELISA is approximately 5% of the R5-ELISA and suggests that barley is the source of the gluten contamination for this sample. In another example, sample 36 reported 59 mg kg−1 using the R5-ELISA and 16 mg kg−1 using the ω-ELISA, suggesting the gluten contamination is likely a mixture of wheat and barley or possibly differences in the ω-gliadin content of sample. The data in Figure 2 indicate that the majority of samples (13 of 14) in the subset that tested positive for gluten were contaminated at some level with barley. Although individuals with gluten sensitivities also react to the hordeins in barley, the actual level of gluten in the sample, measured by the R5-ELISA, can be overestimated due to the differences between barley and wheat, the latter of which has been used to calibrate the method (Kanerva et al. 2006). Canadian regulations do not require allergen labelling of grains like oats that are destined for further processing and allow the presence of a certain percentage of foreign components, which may include gluten-containing cereals (Canadian Grain Regulations 2008). Packagers of oats can voluntary provide precautionary statements to warn allergic or intolerant consumers about the potential risk of cross-contamination. The results of this study have shown that precautionary labelling practices of commercial oats vary greatly (Table 2). For example, the oat products tested either had no precautionary statement pertaining to wheat or gluten (n = 65) or presented various statements ranging from, ‘may contain traces of wheat’ (n = 43) to less clear statements such as ‘good manufacturing practices have been used to segregate ingredients in a facility that also processes peanuts, tree nuts, milk, eggs, wheat, sulfites and soy ingredients’ (n = 11). The latter statement is confusing and contains some uncertainty for many individuals with food allergies (Verrill and Choiniere 2009) and may be a reason why precautionary statements are increasingly being ignored by allergic consumers (Sheth et al. 2010). A concern to no precautionary statement, or an ambiguous one, is a precautionary statement that provides an incomplete list of allergens potentially present through unavoidable cross-contamination. For example, some of the oat samples contained statements indicating the potential presence of other allergens including peanut, tree nuts, sesame and soy, but not for wheat or gluten. Given the increased knowledge of potential cross-contamination a consumer will likely know that these products will still be contaminated with gluten. The only sample that was gluten free in both lots that were tested actually had a wheat-free claim on the package and represents a pure oat product. In regard to oat varieties in Canada it would be suggested that all warnings should be adhered to and avoidance of all commercial oat varieties other than pure oats be followed. Although there were some varieties of prepackaged oats that were low in gluten the vast majority would not be safe for the allergenic or intolerant consumers.
Figure 2.

Results for the determination of gluten source for a subset of samples using two different ELISA kits.

Table 2.

Number of occurrences for different precautionary statements.

Precautionary statementNumber of occurrences
No warning65
Wheat-free claim2
May contain wheat or traces of wheat43
May contain other allergensa9
Manufactured in a facility that also uses wheat, etc.b11
Wheat starch in the ingredient list3

Notes: aExample: ‘May contain traces of nuts and milk ingredients.’

bThis also includes the following statement: ‘Good manufacturing practices have been used to segregate ingredients in a facility that also processes peanuts, tree nuts, milk, eggs, wheat, sulfites and soy ingredients.’

Number of occurrences for different precautionary statements. Notes: aExample: ‘May contain traces of nuts and milk ingredients.’ bThis also includes the following statement: ‘Good manufacturing practices have been used to segregate ingredients in a facility that also processes peanuts, tree nuts, milk, eggs, wheat, sulfites and soy ingredients.’ Results for the determination of gluten source for a subset of samples using two different ELISA kits.

Conclusions

This study was done to determine the extent of the contamination of the commercial oat supply in Canada. Oat samples were collected from retail stores across the country and at different times in the year to ensure two different lots were obtained for each product. Taking into consideration the lot-to-lot variability, approximately 88% of the products tested were contaminated above the Codex-recommended gluten-free level and ranged from 21 to 3800 mg kg−1of oats. There was little difference in the level of gluten between the processed types of oats, but the organic varieties (mean = 240 mg kg−1) did have a statistically significant lower level of gluten compared with the regular variety of oats (mean = 616 mg kg−1). Although the organic varieties of commercial oats contain lower levels of gluten they still would not be considered gluten-free or safe. Further analysis on a portion of the samples collected using a method that is known to have a low sensitivity to barley hordeins indicated that many of these samples were likely contaminated with barley. Only one sample of oats consistently produced negative results using both ELISA methods and this sample contained a wheat-free claim on the package. The pure variety of oats, those that have been determined experimentally to be gluten-free, are the only variety that are recommended for someone following a gluten-restrictive diet. This study also showed that voluntary precautionary labelling was used on roughly half of the products tested and in some cases the statement was inadequate. Therefore, educational initiatives are important in communicating the risk of gluten contamination in naturally gluten-free cereal grains such as (regular) commercial oats. Initiatives are underway to collect data on the gluten contamination of other naturally gluten-free cereal grains in Canada, which may have an important impact on the consumption patterns of individuals with celiac disease or wheat allergy in Canada.

Acknowledgements

The authors would like to thank CFIA and the Toronto Regional Laboratory for collecting and distributing the oat samples. They also thank Bob Dabeka and John Moisey for helpful comments on this manuscript.
  17 in total

Review 1.  Celiac sprue.

Authors:  Richard J Farrell; Ciarán P Kelly
Journal:  N Engl J Med       Date:  2002-01-17       Impact factor: 91.245

2.  Gluten contamination of commercial oat products in the United States.

Authors:  Tricia Thompson
Journal:  N Engl J Med       Date:  2004-11-04       Impact factor: 91.245

3.  Confirmation of the cereal type in oat products highly contaminated with gluten.

Authors:  Alberto Hernando; Jorge Raul Mujico; David Juanas; Enrique Méndez
Journal:  J Am Diet Assoc       Date:  2006-05

4.  Measurement of wheat gluten and barley hordeins in contaminated oats from Europe, the United States and Canada by Sandwich R5 ELISA.

Authors:  Alberto Hernando; Jorge R Mujico; María C Mena; Manuel Lombardía; Enrique Méndez
Journal:  Eur J Gastroenterol Hepatol       Date:  2008-06       Impact factor: 2.566

Review 5.  Coeliac disease and oats: a systematic review.

Authors:  N Y Haboubi; S Taylor; S Jones
Journal:  Postgrad Med J       Date:  2006-10       Impact factor: 2.401

6.  Gluten-free diet survey: are Americans with coeliac disease consuming recommended amounts of fibre, iron, calcium and grain foods?

Authors:  T Thompson; M Dennis; L A Higgins; A R Lee; M K Sharrett
Journal:  J Hum Nutr Diet       Date:  2005-06       Impact factor: 3.089

7.  Identification of IgE-binding epitopes on gliadins for patients with food allergy to wheat.

Authors:  F Battais; T Mothes; D A Moneret-Vautrin; F Pineau; G Kanny; Y Popineau; M Bodinier; S Denery-Papini
Journal:  Allergy       Date:  2005-06       Impact factor: 13.146

Review 8.  Review article: safe amounts of gluten for patients with wheat allergy or coeliac disease.

Authors:  C Hischenhuber; R Crevel; B Jarry; M Mäki; D A Moneret-Vautrin; A Romano; R Troncone; R Ward
Journal:  Aliment Pharmacol Ther       Date:  2006-03-01       Impact factor: 8.171

9.  Avenins from different cultivars of oats elicit response by coeliac peripheral lymphocytes.

Authors:  Marco Silano; Rita Di Benedetto; Francesca Maialetti; Alessandro De Vincenzi; Roberta Calcaterra; Hugh J Cornell; Massimo De Vincenzi
Journal:  Scand J Gastroenterol       Date:  2007-11       Impact factor: 2.423

10.  Consumption of pure oats by individuals with celiac disease: a position statement by the Canadian Celiac Association.

Authors:  Mohsin Rashid; Decker Butzner; Vernon Burrows; Marion Zarkadas; Shelley Case; Mavis Molloy; Ralph Warren; Olga Pulido; Connie Switzer
Journal:  Can J Gastroenterol       Date:  2007-10       Impact factor: 3.522

View more
  19 in total

Review 1.  Advances in diagnosis and management of celiac disease.

Authors:  Ciarán P Kelly; Julio C Bai; Edwin Liu; Daniel A Leffler
Journal:  Gastroenterology       Date:  2015-02-03       Impact factor: 22.682

Review 2.  The gluten-free diet and its current application in coeliac disease and dermatitis herpetiformis.

Authors:  Carolina Ciacci; Paul Ciclitira; Marios Hadjivassiliou; Katri Kaukinen; Jonas F Ludvigsson; Norma McGough; David S Sanders; Jeremy Woodward; Jonathan N Leonard; Gillian L Swift
Journal:  United European Gastroenterol J       Date:  2015-04       Impact factor: 4.623

3.  Patients with celiac disease are not followed up adequately.

Authors:  Margot L Herman; Alberto Rubio-Tapia; Brian D Lahr; Joseph J Larson; Carol T Van Dyke; Joseph A Murray
Journal:  Clin Gastroenterol Hepatol       Date:  2012-05-18       Impact factor: 11.382

4.  AGY, a Novel Egg Yolk-Derived Anti-gliadin Antibody, Is Safe for Patients with Celiac Disease.

Authors:  Dory A Sample; Hoon H Sunwoo; Hien Q Huynh; Heather L Rylance; Cheri L Robert; Bi-Wen Xu; Sung H Kang; Naiyana Gujral; Levinus A Dieleman
Journal:  Dig Dis Sci       Date:  2016-12-29       Impact factor: 3.199

5.  Exposure sources, amounts and time course of gluten ingestion and excretion in patients with coeliac disease on a gluten-free diet.

Authors:  Jocelyn A Silvester; Isabel Comino; Lisa N Rigaux; Veronica Segura; Kathy H Green; Angel Cebolla; Dayna Weiten; Remedios Dominguez; Daniel A Leffler; Francisco Leon; Charles N Bernstein; Lesley A Graff; Ciaran P Kelly; Carolina Sousa; Donald R Duerksen
Journal:  Aliment Pharmacol Ther       Date:  2020-09-27       Impact factor: 8.171

6.  ACG clinical guidelines: diagnosis and management of celiac disease.

Authors:  Alberto Rubio-Tapia; Ivor D Hill; Ciarán P Kelly; Audrey H Calderwood; Joseph A Murray
Journal:  Am J Gastroenterol       Date:  2013-04-23       Impact factor: 10.864

Review 7.  Role of oats in celiac disease.

Authors:  Isabel Comino; María de Lourdes Moreno; Carolina Sousa
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

8.  Food production and processing considerations of allergenic food ingredients: a review.

Authors:  Pedro A Alvarez; Joyce I Boye
Journal:  J Allergy (Cairo)       Date:  2011-12-01

9.  Long-term consumption of oats in adult celiac disease patients.

Authors:  Katri Kaukinen; Pekka Collin; Heini Huhtala; Markku Mäki
Journal:  Nutrients       Date:  2013-11-06       Impact factor: 5.717

Review 10.  A Systematic Review on Gluten-Free Bread Formulations Using Specific Volume as a Quality Indicator.

Authors:  Jordanna S Monteiro; Priscila Farage; Renata Puppin Zandonadi; Raquel B A Botelho; Livia de L de Oliveira; António Raposo; Faiyaz Shakeel; Sultan Alshehri; Wael A Mahdi; Wilma M C Araújo
Journal:  Foods       Date:  2021-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.